---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-015213"
form_type: "8-K"
ticker: "HURA"
cik: "0001498382"
company_name: "TuHURA Biosciences, Inc./NV"
filed_at: "2024-02-14T23:59:59+00:00"
generated_at: "2026-06-06T02:15:37.506021+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Kintara Q2 net loss $1.0M; starts REM-001 CMBC study, explores strategic alternatives

## Summary
- Q2 net loss $1.0M ($0.24/share) vs $3.5M ($2.10/share) year earlier; R&D fell to $0.1M from $2.1M.
- Cash $0.7M at Dec 31, 2023; raised $6.1M net via ATM from Jan 1-Feb 12, 2024.
- Initiated 15-patient REM-001 study in cutaneous metastatic breast cancer; costs covered by $2.0M SBIR grant from NIH.
- Board reviewing strategic alternatives to maximize stockholder value; Ladenburg Thalmann engaged as financial advisor (Dec 2023).
- VAL-083 development terminated after failure in GBM AGILE study (Oct 2023).

## SEC filing metadata
- accession: 0000950170-24-015213
- form_type: 8-K
- ticker: HURA
- cik: 0001498382
- company_name: TuHURA Biosciences, Inc./NV
- filed_at: 2024-02-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1498382/000095017024015213/0000950170-24-015213-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1498382/000095017024015213/ktra-20240214.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-015213
- JSON: https://secwatch.observer/filing/0000950170-24-015213.json
- Plain text: https://secwatch.observer/filing/0000950170-24-015213.txt

## Key facts
- Earnings Releases
  TuHURA Biosciences, Inc./NV reported fiscal 2024 second quarter ended December 31, 2023 results: net income $1.0 million, EPS $0.24 per share.
  - Period: fiscal 2024 second quarter ended December 31, 2023
  - Net income: $1.0 million
  - EPS: $0.24 per share
  - Result: reported results
  source text: For the three months ended December 31, 2023, Kintara reported a net loss of approximately $1.0 million, or $0.24 per share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1498382/000095017024015213/0000950170-24-015213-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.